OmniAb, Inc.

NASDAQ:OABI

Biotechnology

Healthcare
$5.08 +7.88%

+$0.16 today

Market cap
$740.97M
Beta
1.15
P/E (TTM)
-5.2
EPS (TTM)
-$0.42
52W Low $1.30High $2.79

Volume 1.22M

Average 0.67M

OABI Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

OmniAb, Inc.NASDAQ: OABI

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $8.4M rose 102.2% year over year, ahead of the -61.7% change in trailing-twelve-month gross profit. Sequentially, it rose 1172.7% from the prior quarter.

Context

  • Gross profit amounted to 18.2% of revenue in FY2025, down 81.8 pp from a year earlier.
  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +102.2% holds above the trailing-twelve-month pace of -61.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.4M+1172.7% QoQ
Last fiscal yearDec 2025
-$3.39M-112.8% YoY
LTMMar 2026
$10.25M-61.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+102.2%——
1 year-112.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(3.39M) USD
Year-over-year change
-112.8%

Gross Profit vs competitors

How OABI compares with its peers on the latest reported figures

  • OABI's LTM Mar 2026 gross profit of $10.25M is the 3rd highest of the 4 companies compared; the peer median is $98.33M.
  • Its year-over-year change of -61.7% is the lowest of 4, against a peer median of +48.7%.
  • Gross profit amounts to 35.5% of revenue for OABI, versus a peer median of 98.7%.
OABI Competitors Peer median
Gross Profit for OABI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M +16.2%-9.3%69.9%
STROSutro Biopharma, Inc.LTM Mar 2026$98.33M +52.1%+17.0%98.7%
OABIOmniAb, Inc.LTM Mar 2026$10.25M -61.7%—35.5%
ABSIAbsci CorporationLTM Mar 2026-$24.18M +48.7%—1316.9%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding OABI) $98.33M+48.7%+3.8%98.7%

Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.75M59.08M34.16M26.39M18.67M
Cost of Revenue000022.06M
Gross Profit34.75M59.08M34.16M26.39M(3.39M)
Gross Margin100.0%100.0%100.0%100.0%-18.2%
Research & Development39.23M48.36M56.53M55.11M47.75M
Selling, General & Admin16.95M24.9M33.31M30.74M29.22M
Operating Expenses70.36M85.73M103.58M100.89M68.13M
Depreciation & Amortization16.25M18.25M19.5M23.58M21.75M
EBITDA(18.09M)(7.81M)(44.87M)(47.83M)(44.54M)
EBITDA Margin-52.1%-13.2%-131.3%-181.2%-238.6%
Operating Income(35.61M)(26.65M)(69.42M)(74.5M)(71.52M)
Operating Margin-102.5%-45.1%-203.2%-282.3%-383.1%
Interest Income0587K5.06M3.11M2.66M
Interest Expense7K0000
Other Income / Expenses1.26M587K5.06M3.09M5.22M
Income Before Tax(34.35M)(26.06M)(64.36M)(71.41M)(66.29M)
Pre-Tax Margin-98.9%-44.1%-188.4%-270.6%-355.2%
Income Tax Expense(7.31M)(3.73M)(13.74M)(9.38M)(1.52M)
Net Income(27.04M)(22.33M)(50.62M)(62.03M)(64.78M)
Net Margin-77.8%-37.8%-148.2%-235.1%-347.0%
EPS (Basic)(0.24)(0.26)(0.51)(0.61)(0.57)
EPS (Diluted)(0.24)(0.26)(0.51)(0.61)(0.57)
Weighted Avg Shares114.82M85.32M99.68M102.37M113.64M
Weighted Avg Shares (Diluted)114.82M85.32M99.68M102.37M113.64M

OmniAb, Inc.

NASDAQ:OABI

Intrinsic Alpha fair value

Locked

Current Price

$5.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.